251 related articles for article (PubMed ID: 22543528)
1. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.
Schettini J; Kidiyoor A; Besmer DM; Tinder TL; Roy LD; Lustgarten J; Gendler SJ; Mukherjee P
Cancer Immunol Immunother; 2012 Nov; 61(11):2055-65. PubMed ID: 22543528
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
[TBL] [Abstract][Full Text] [Related]
3. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
4. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
5. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer.
Jahrsdörfer B; Weiner GJ
Semin Oncol; 2003 Aug; 30(4):476-82. PubMed ID: 12939716
[TBL] [Abstract][Full Text] [Related]
7. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
[TBL] [Abstract][Full Text] [Related]
8. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.
Warren TL; Dahle CE; Weiner GJ
Clin Lymphoma; 2000 Jun; 1(1):57-61. PubMed ID: 11707814
[TBL] [Abstract][Full Text] [Related]
9. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
10. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
Alderson KL; Luangrath M; Elsenheimer MM; Gillies SD; Navid F; Rakhmilevich AL; Sondel PM
Cancer Immunol Immunother; 2013 Apr; 62(4):665-75. PubMed ID: 23151945
[TBL] [Abstract][Full Text] [Related]
12. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.
Garbi N; Arnold B; Gordon S; Hämmerling GJ; Ganss R
J Immunol; 2004 May; 172(10):5861-9. PubMed ID: 15128765
[TBL] [Abstract][Full Text] [Related]
13. Activation of natural killer-like YT-INDY cells by oligodeoxynucleotides and binding by homologous pattern recognition proteins.
Kaur H; Jaso-Friedmann L; Leary JH; Praveen K; Brahmi Z; Evans DL
Scand J Immunol; 2005 Oct; 62(4):361-70. PubMed ID: 16253123
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-21 enhances NK cell activation in response to antibody-coated targets.
Roda JM; Parihar R; Lehman A; Mani A; Tridandapani S; Carson WE
J Immunol; 2006 Jul; 177(1):120-9. PubMed ID: 16785506
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
17. Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells.
Sivori S; Carlomagno S; Moretta L; Moretta A
Eur J Immunol; 2006 Apr; 36(4):961-7. PubMed ID: 16525994
[TBL] [Abstract][Full Text] [Related]
18. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
Wang SY; Racila E; Taylor RP; Weiner GJ
Blood; 2008 Feb; 111(3):1456-63. PubMed ID: 18024795
[TBL] [Abstract][Full Text] [Related]
19. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
[TBL] [Abstract][Full Text] [Related]
20. Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta.
Rothenfusser S; Hornung V; Krug A; Towarowski A; Krieg AM; Endres S; Hartmann G
Eur J Immunol; 2001 Dec; 31(12):3525-34. PubMed ID: 11745372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
